Psoriasis vulgaris treated successfully with mycophenolate mofetil

The British Journal of Dermatology
M G HaufsT A Luger

Abstract

Mycophenolate mofetil (MMF) is a new immunosuppressive drug which non-competitively and reversibly blocks the de novo synthesis of guanine nucleotides required for DNA and RNA synthesis during T- and B-cell proliferation. This induces a selective inhibition of lymphocyte proliferation. Thus MMF is currently used to prolong graft survival in renal transplant patients. In this communication we describe the first case of a man with severe psoriasis treated successfully with oral MMF without short-term side-effects. The psoriasis area and severity index score decreased during therapy (5 weeks) from 22.0 to 11.4. Thus MMF appears to be an effective therapeutic alternative in the treatment of severe psoriasis.

References

Jul 1, 1977·Archives of Dermatology·R MarinariA L Rosenthal
Dec 1, 1975·The Journal of Investigative Dermatology·E L JonesP Frost
Aug 1, 1990·The Journal of Investigative Dermatology·M L TurbittR M MacKie
Nov 1, 1988·The British Journal of Dermatology·A Ramirez-BoscaA Castells-Rodellas
Dec 1, 1987·Journal of the American Academy of Dermatology·W W EpinetteM C Greist
Jul 1, 1983·The British Journal of Dermatology·M W Greaves
Jan 1, 1993·Springer Seminars in Immunopathology·A C Allison, E M Eugui
Jul 1, 1996·International Archives of Allergy and Immunology·E Christophers
Feb 1, 1997·Nature Medicine·M P SchönC M Parker
Feb 22, 1997·Lancet·M BöhmT Luger

❮ Previous
Next ❯

Citations

Jul 6, 2000·Immunopharmacology·A C Allison, E M Eugui
Nov 26, 2003·Journal of the American Academy of Dermatology·Uta FrielingStefan Beissert
Jan 22, 2002·Trends in Immunology·Khusru AsadullahWolfram Sterry
Aug 22, 2000·The British Journal of Dermatology·S C DavisonL Fry
Mar 22, 2001·The British Journal of Dermatology·C C GeilenC E Orfanos
Mar 22, 2001·The British Journal of Dermatology·A Benez, G Fierlbeck
Jun 26, 2001·The British Journal of Dermatology·J WohlrabW C Marsch
Jul 9, 2002·The British Journal of Dermatology·S SchanzG Fierlbeck
Oct 27, 2001·Clinical and Experimental Dermatology·M AmeenJ N Barker
Dec 5, 2002·Clinical and Experimental Dermatology·U Frieling, T A Luger
Feb 24, 2001·Australian and New Zealand Journal of Medicine·L WallmanD Fulcher
Jan 15, 2005·Journal of the European Academy of Dermatology and Venereology : JEADV·V SchleyerR-M Szeimies
Sep 17, 2013·Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire·J BorowczykJ Drukala
Apr 30, 2002·American Journal of Clinical Dermatology·Jennifer Cather, Alan Menter
Nov 17, 2010·Indian Journal of Dermatology, Venereology and Leprology·Amrinder J KanwarSunil Dogra
Oct 10, 1998·The British Journal of Dermatology·B Kirby, V M Yates
Dec 9, 2003·The Journal of Dermatological Treatment·V Liu, B T Mackool
Nov 4, 2000·Expert Opinion on Investigational Drugs·D DiSepio, R A Chandraratna
Nov 4, 2000·Expert Opinion on Investigational Drugs·D D Gladman, J Brockbank
Jan 20, 2009·Journal of the American Academy of Dermatology·Alissa K OrvisShannon W Watkins
Jul 14, 2006·Journal of the European Academy of Dermatology and Venereology : JEADV·J PedrazA García-Díez
Feb 20, 1999·Journal of the American Academy of Dermatology·H C NousariG J Anhalt
Aug 16, 2000·Dermatologic Clinics·F Flores, F A Kerdel
Jan 13, 2001·Dermatologic Clinics·N G Silvis
Apr 20, 2005·Dermatologic Clinics·Dana Kazlow SternMark Lebwohl
Sep 25, 2012·The Journal of Dermatological Treatment·Shiva Fallah AraniBing Thio
Dec 13, 2006·International Immunopharmacology·Toshihiko Hirano
Feb 25, 2000·Journal of the American Academy of Dermatology·K H KatzK F Helm
Apr 5, 2005·Lupus·M Hartmann, A Enk
Dec 21, 2000·The British Journal of Dermatology·E R HansenK E Andersen
Aug 17, 2002·The Journal of Pharmacology and Experimental Therapeutics·Jugnu JainCaroline Decker
Nov 16, 2005·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Markus FriedrichKhusru Asadullah
Aug 18, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·A MehlingS Beissert
Jan 25, 2019·The Journal of Dermatological Treatment·Jenny Sung Won YunLaura Scardamaglia
Jun 26, 2001·Clinical and Experimental Dermatology·U Mrowietz
Apr 5, 2001·Journal of Pharmaceutical Sciences·J JainM W Harding
Jun 8, 2001·Journal of Chromatography. B, Biomedical Sciences and Applications·M PlätzerR H Neubert
Nov 15, 2002·Transplantation Proceedings·Y QuirozB Rodriguez-Iturbe
Apr 25, 2000·Journal of the American Academy of Dermatology·M Grundmann-KollmannR U Peter
Apr 25, 2000·Journal of the American Academy of Dermatology·C C Geilen, U Mrowietz

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.